SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity - 12/05/21
, Giovanni Sotgiu c, Laura Saderi c, Antonio Voza d, Stefano Aliberti a, b, Francesco Amati a, b
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Non-pharmacological interventions and tracing-testing strategy proved insufficient to reduce SARS-CoV-2 spreading worldwide. Several vaccines with different mechanisms of action are currently under development. This review describes the potential target antigens evaluated for SARS-CoV-2 vaccine in the context of both conventional and next-generation platforms.
We reported experimental data from phase-3 trials with a focus on different definitions of efficacy as well as factors affecting real-life effectiveness of SARS-CoV-2 vaccination, including logistical issues associated to vaccine availability, delivery, and immunization strategies. On this background, new variants of SARS-CoV-2 are discussed.
We also provided a critical view on vaccination in special populations at higher risk of infection or severe disease as elderly people, pregnant women and immunocompromised patients. A final paragraph addresses safety on the light of the unprecedented reduction of length of the vaccine development process and faster authorization.
Il testo completo di questo articolo è disponibile in PDF.Highlights |
• | A global vaccination strategy based on efficacious vaccines is among the most relevant unmet needs in COVID-19 management. |
• | Vaccine platforms can be conventional and next generation. To date, phase-3 trials are published for 4 vaccines. |
• | The definition of vaccine efficacy is challenging and clinical endpoints are heterogeneous. |
• | Several factors might affect the effectiveness of a mass vaccination and the herd immunity. |
Keywords : SARS-CoV-2, COVID-19, Vaccination, Primary prevention
Mappa
Vol 180
Articolo 106355- aprile 2021 Ritorno al numero
Articolo precedente
- COVID-19: Why does disease severity vary among individuals?
- Saeed Samadizadeh, Maha Masoudi, Mostafa Rastegar, Vahid Salimi, Mahsa Bataghva Shahbaz, Alireza Tahamtan
- Mouthpiece ventilation in neuromuscular disorders: Narrative review of technical issues important for clinical success
- Michel Toussaint, Michelle Chatwin, Miguel R. Gonçalves, Jésus Gonzalez-Bermejo, Joshua O. Benditt, Doug McKim, Jesus Sancho, Brit Hov, Valeria Sansone, Hélène Prigent, Annalisa Carlucci, Peter Wijkstra, Barbara Garabelli, Joan Escarrabill, Tiago Pinto, Nicolas Audag, Laura Verweij-van den Oudenrijn, Adam Ogna, Wendy Hughes, Christian Devaux, Johann Chaulet, Tiina Andersen, ENMC Respiratory Therapy Consortium
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.